Compare Stitch Fix Inc (SFIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs TG Therapeutics Inc — how do they compare? Stitch Fix Inc trades at $2.9 (market cap $385.60M), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: TG Therapeutics Inc is far larger — about 21.7× Stitch Fix Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | TGTX | |
|---|---|---|
Market Cap | $385.60M | $8.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.80 | $59.06 |
52-Week Low | $2.89 | $26.94 |
Enterprise Value | $273.32M | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, reflecting ongoing investor caution despite recent operational improvements. The stock is technically bearish with key moving averages signaling selling pressure, while fundamentals show a narrowing net loss margin to -2.27% in 2025 from -9.64% in 2024, alongside a low price-to-sales ratio of 0.3. Recent news highlights AI-driven personalization efforts and exclusive brand collaborations aimed at boosting client engagement and revenue per user.
The outlook remains mixed; cost controls and revenue stabilization offer a path to profitability, but persistent net losses and competitive pressures pose risks. Analyst sentiment is cautious with a 63.64% hold rating, suggesting investors await clearer signs of a sustained turnaround before committing capital.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
